Home Previous Slide◀︎ Next Slide▶︎ UCB, a global biopharma company headquartered in Brussels, Belgium, focused on developing treatments for severe neurological and immunological diseases We always strive to find new ways to deliversolutions to people living with severe diseases Everyone deserves to live the best life that they can We act with care to create value in the lives of the people we serve Current Slide Current Slide Current Slide Current Slide
UCB, a global biopharma company headquartered in Brussels, Belgium, focused on developing treatments for severe neurological and immunological diseases
Improving the lives of people living with neurological and autoimmune diseasesUCB is a global biopharmaceutical company headquartered in Belgium and active in nearly 40 countries. UCB is focused on researching, developing and delivering innovative medicines and patient solutions for people living with neurological and autoimmune diseases including epilepsy, psoriasis, osteoporosis, and more. We combine scientific innovation, patient insights, and global expertise to address unmet medical needs and improve quality of life. Discover more about us What is UCBCares®? UCB Cares® is a patient support program designed to help people living with chronic diseases and healthcare professionals throughout the treatment journey. We listen first, then respond with practical, personal guidance. Explore UCBCares® patient support How UCB Innovates? Innovation at UCB spans drug discovery, clinical development, digital health, patient engagement, and strategic partnerships with academic institutions and biotechnology companies. Our research focuses on advancing treatments for severe neurological and autoimmune diseases. Explore innovation at UCB Latest news and stories Explore the latest UCB news, scientific achievements, financial news, stories, research updates, corporate announcements, and sustainability progress. Visit our newsroom Story Why minimal symptom expression matters: raising the bar for people living with myasthenia gravis Read More Story 25 Sep 2026 The best conversations start early: coffee reflections ahead of EADV 2026 Read More Story 8 Sep 2026 Helping families and clinicians connect the signs that may point to TK2d Read More Press release 30 Sep 2026 UCB announces new data at EADV 2026 supporting earlier use of BIMZELX[®] (bimekizumab) for treating... Read More Press release 29 Sep 2026 UCB data presented at 2026 AANEM Annual Meeting and MGFA Scientific Session underscore leadership in... Read More Sustainability at the heart of what we do Our approach to sustainability builds on the areas where we can make the greatest difference: scientific innovation, equitable access to medicines, patient engagement, health, safety and wellbeing of our people, health of the planet, inclusion, and ethical business practices. Lear more about our sustainability approach Woman of Childbearing Age UCB’s mission is to empower women of childbearing age living with chronic diseases to make informed decisions about their healthcare. Our vision is to advance science in the care of these women, as we believe they should be protected through research – not from it. Learn more about our mission
Story 25 Sep 2026 The best conversations start early: coffee reflections ahead of EADV 2026 Read More
Press release 30 Sep 2026 UCB announces new data at EADV 2026 supporting earlier use of BIMZELX[®] (bimekizumab) for treating... Read More
Press release 29 Sep 2026 UCB data presented at 2026 AANEM Annual Meeting and MGFA Scientific Session underscore leadership in... Read More